Clinical Edge Journal Scan

Cognitive impairment is a manifestation of PsA


 

Key clinical point : Cognitive impairment may be one of the neurological manifestations of psoriatic arthritis (PsA).

Major finding : Patients with PsA scored worse on the Montreal Cognitive Assessment (MoCA) vs. controls ( P = .01). Additionally, the proportion of patients with cognitive impairment according to MoCA was significantly higher among cases vs. controls (91.9% vs. 58.3%, P = .002).

Study details : The data come from a cross-sectional case-control study involving 37 patients with PsA and 36 healthy controls.

Disclosures: The study did not receive any funding. The authors declared no conflicts of interest.

Source: Garcia LOKL et al. Acta Neurol Belg. 2021 Mar 13. doi: 10.1007/s13760-021-01644-y .

Recommended Reading

Checkpoint inhibitor–induced rheumatic complications often arise late
MDedge Rheumatology
FDA warning letters target OTC cannabidiol product claims for pain relief
MDedge Rheumatology
COVID-19 vaccination in RMD patients: Safety data “reassuring”
MDedge Rheumatology
Experts highlight recent breakthroughs in psoriatic arthritis
MDedge Rheumatology
Is pain linked to mortality risk in patients with psoriatic arthritis?
MDedge Rheumatology
PsA: Brodalumab demonstrates favorable efficacy in phase 3 trials
MDedge Rheumatology
Continuing ixekizumab superior to withdrawal in stable psoriatic arthritis
MDedge Rheumatology
Risk factors for progression from subclinical to clinical psoriatic arthritis
MDedge Rheumatology
Depression and anxiety linked to reduced probability of achieving sustained MDA in PsA
MDedge Rheumatology
Intravenous golimumab improves HRQoL and productivity in patients with active PsA
MDedge Rheumatology